Weiss Ratings Reiterates Buy (B-) Rating for Dr. Reddy’s Laboratories (NYSE:RDY)

Dr. Reddy’s Laboratories (NYSE:RDY)‘s stock had its “buy (b-)” rating reiterated by Weiss Ratings in a report issued on Friday,Weiss Ratings reports.

Separately, Zacks Research upgraded Dr. Reddy’s Laboratories from a “strong sell” rating to a “hold” rating in a report on Friday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $16.95.

Dr. Reddy’s Laboratories Stock Performance

RDY stock opened at $14.62 on Friday. The business’s 50-day moving average price is $14.36 and its two-hundred day moving average price is $14.38. The company has a current ratio of 1.89, a quick ratio of 1.36 and a debt-to-equity ratio of 0.01. The firm has a market cap of $12.20 billion, a PE ratio of 22.14, a P/E/G ratio of 5.75 and a beta of 0.40. Dr. Reddy’s Laboratories has a 1-year low of $12.26 and a 1-year high of $16.17.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its earnings results on Friday, October 24th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.25% and a net margin of 16.99%. As a group, research analysts forecast that Dr. Reddy’s Laboratories will post 0.8 earnings per share for the current year.

Institutional Trading of Dr. Reddy’s Laboratories

Institutional investors have recently modified their holdings of the company. Costello Asset Management INC bought a new stake in shares of Dr. Reddy’s Laboratories in the first quarter valued at about $26,000. Westside Investment Management Inc. bought a new stake in shares of Dr. Reddy’s Laboratories in the second quarter valued at about $35,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Dr. Reddy’s Laboratories by 71.7% in the second quarter. EverSource Wealth Advisors LLC now owns 3,100 shares of the company’s stock valued at $47,000 after purchasing an additional 1,294 shares in the last quarter. Allworth Financial LP lifted its holdings in shares of Dr. Reddy’s Laboratories by 28.4% in the first quarter. Allworth Financial LP now owns 3,504 shares of the company’s stock valued at $49,000 after purchasing an additional 776 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Dr. Reddy’s Laboratories by 217.4% in the third quarter. Farther Finance Advisors LLC now owns 3,568 shares of the company’s stock valued at $50,000 after purchasing an additional 2,444 shares in the last quarter. 3.85% of the stock is currently owned by institutional investors.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.